Biohaven Market Cap 2016-2022 | BHVN

Biohaven market cap history and chart from 2016 to 2022. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Biohaven market cap as of February 03, 2023 is $1.24B.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.240B $0.463B
Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00